收费全文 | 18071篇 |
免费 | 1048篇 |
国内免费 | 46篇 |
耳鼻咽喉 | 245篇 |
儿科学 | 428篇 |
妇产科学 | 209篇 |
基础医学 | 2309篇 |
口腔科学 | 641篇 |
临床医学 | 1581篇 |
内科学 | 3592篇 |
皮肤病学 | 367篇 |
神经病学 | 1984篇 |
特种医学 | 1248篇 |
外国民族医学 | 1篇 |
外科学 | 2722篇 |
综合类 | 154篇 |
一般理论 | 4篇 |
预防医学 | 1505篇 |
眼科学 | 390篇 |
药学 | 851篇 |
中国医学 | 14篇 |
肿瘤学 | 920篇 |
2021年 | 252篇 |
2020年 | 160篇 |
2019年 | 191篇 |
2018年 | 284篇 |
2017年 | 218篇 |
2016年 | 244篇 |
2015年 | 317篇 |
2014年 | 442篇 |
2013年 | 576篇 |
2012年 | 810篇 |
2011年 | 845篇 |
2010年 | 539篇 |
2009年 | 465篇 |
2008年 | 840篇 |
2007年 | 896篇 |
2006年 | 832篇 |
2005年 | 841篇 |
2004年 | 757篇 |
2003年 | 724篇 |
2002年 | 731篇 |
2001年 | 651篇 |
2000年 | 608篇 |
1999年 | 497篇 |
1998年 | 199篇 |
1997年 | 143篇 |
1996年 | 126篇 |
1995年 | 161篇 |
1994年 | 139篇 |
1993年 | 123篇 |
1992年 | 338篇 |
1991年 | 368篇 |
1990年 | 310篇 |
1989年 | 286篇 |
1988年 | 268篇 |
1987年 | 238篇 |
1986年 | 255篇 |
1985年 | 258篇 |
1984年 | 201篇 |
1983年 | 182篇 |
1982年 | 125篇 |
1981年 | 123篇 |
1980年 | 120篇 |
1979年 | 241篇 |
1978年 | 156篇 |
1977年 | 149篇 |
1975年 | 148篇 |
1974年 | 128篇 |
1973年 | 135篇 |
1972年 | 142篇 |
1970年 | 117篇 |
Background
Treatment of advanced anal squamous cell cancer (SCC) is usually with the combination of cisplatin and 5-fluorouracil, which is associated with heterogeneous responses across patients and significant toxicity. We examined the safety and efficacy of a modified schedule, FOLFCIS (leucovorin, fluorouracil, and cisplatin), and performed an integrated clinical and genomic analysis of anal SCC.Patients and Methods
We reviewed all patients with advanced anal SCC receiving first-line FOLFCIS chemotherapy – essentially a FOLFOX (leucovorin, fluorouracil, and oxaliplatin) schedule with cisplatin substituted for oxaliplatin – in our institution between 2007 and 2017, and performed deep sequencing to identify genomic markers of response and key genomic drivers.Results
Fifty-three patients with advanced anal SCC (48 metastatic; 5 unresectable, locally advanced) received first-line FOLFCIS during this period; all were platinum-naive. The response rate was 48% (95% confidence interval [CI], 32.6%-63%). With a median follow-up of 41.6 months, progression-free survival and overall survival were 7.1 months (95% CI, 4.4-8.6 months) and 22.1 months (95% CI, 16.9-28.1 months), respectively. Among all patients with advanced anal SCC that underwent sequencing during the study period, the most frequent genomic alterations consisted of chromosome 3q amplification (51%) and mutations in PIK3CA (29%) and KMT2D (22%). No genomic alteration correlated with response to platinum-containing treatment. Although there were few cases, patients with human papillomavirus-negative anal SCC did not appear to benefit from FOLFCIS, and all harbored distinct genomic profiles with TP53, TERT promoter, and CDKN2A mutations.Conclusions
FOLFCIS appears effective and safe as first-line chemotherapy in patients with advanced anal SCC and represents an alternative treatment option for these patients. 相似文献Areas covered: This review focuses on current treatments and the future outlook for allergic rhinitis. Pharmacotherapy includes mast cell stabilizers, antihistamines, glucocorticosteroids (GCSs), leukotriene receptor antagonists, and nasal decongestants. Nasal GCSs are currently regarded as the most effective treatment and are considered first-line therapy together with non-sedating antihistamines. The new formulation MP29-02 combines the nasal GCS fluticasone propionate with azelastine in one single spray and has achieved greater improvements than those under monotherapy with modern GCSs or antihistamines. Furthermore, this review discusses allergen immunotherapy alone and in combination with modern monoclonal antibodies.
Expert opinion: Despite the variety of medications for allergic rhinitis, ranging from general symptomatic agents like GCSs or decongestants, to more specific ones like histamine receptor or leukotriene blockers, to causal therapy like immunotherapy, many patients still experience treatment failures or unsatisfactory results. The ultimate goal may be to endotype every downstream pathway separately in order to offer patients individualized, targeted therapy with specific antibodies against the respective pathway. 相似文献